Skip to main content

Table 1 Validation of DVH estimation model by applying it to similar cases: dosimetric comparison between the 10 clinical supine VMAT plans and their knowledge-based re-optimizations

From: Applying a RapidPlan model trained on a technique and orientation to another: a feasibility and dosimetric evaluation

 

Mean

SD

95 % Confidence intervals

(%)

P

Lower

Upper

HI_PGTV

Original

0.06

0.01

0.05

0.07

0.01

0.15*

RP-VMAT

0.05

0.01

0.05

0.06

HI_PTV

Original

0.26

0.01

0.25

0.27

0

0.62*

RP-VMAT

0.26

0.01

0.25

0.27

CI_PGTV

Original

1.01

0.04

0.98

1.04

0.01

0.11

RP-VMAT

1.00

0.04

0.97

1.03

CI_PTV

Original

1.03

0.02

1.02

1.05

0.01

0.05*

RP-VMAT

1.02

0.02

1.01

1.04

Dmax

Original

53.93

0.35

53.69

54.18

0.36 (0.67 %)

0.07*

RP-VMAT

53.57

0.50

53.22

53.93

D2 %

Original

53.37

0.37

53.10

53.63

0.34 (0.64 %)

0.15*

RP-VMAT

53.03

0.46

52.70

53.36

D50 %_UB

Original

28.90

5.31

25.10

32.69

5.39 (18.65 %)

0.01

RP-VMAT

23.51

3.26

21.18

25.84

D50 %_FH

Original

16.30

1.66

15.11

17.48

2.30 (14.11 %)

0.01

RP-VMAT

14.00

0.92

13.34

14.65

Dmean_UB

Original

30.01

4.52

26.77

33.24

4.51 (15.03 %)

0.01

RP-VMAT

25.50

1.54

24.40

26.60

Dmean_FH

Original

17.18

1.80

15.90

18.47

1.85 (10.77 %)

0.01

RP-VMAT

15.33

0.68

14.85

15.82

MUs

Original

412

41

383

441

18 (4.37 %)

0.14

RP-VMAT

430

23

413

447

  1. Abbreviations: HI homogeneity index, CI conformity index, D max global maximum dose, D 2 % near maximum dose, SD standard deviation, (%) difference between the original and RP-VMAT plans (% relative to the original value), D 50 % dose to the 50 % volume of the structure, D mean mean dose, FH femoral head, UB urinary bladder, MU monitor unit, RP-VMAT volumetric modulated arc therapy plans optimized by RapidPlan. Dose unit (Gy)
  2. *Paired sample T test, otherwise Wilcoxon signed ranks test was used